Abstract
Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have